MedVi Expands Access to GLP-1 Medication - Compounded Semaglutide for Healthy Living

The GLP-1 medication program by MedVi is now available nationwide starting at $179.
NEWARK, DE - MedVi Wellness, a leading telehealth provider in medical weight management, has announced the launch of its nationwide GLP-1 medication program, providing compounded semaglutide in both injectable and oral forms. Starting at $179 per month with no insurance required, MedVi [https://medvi.io] offers an affordable, physician-guided alternative to high-cost brand-name drugs such as Wegovy Registered and Ozempic Registered .

The GLP-1 medication program combines compounded semaglutide with continuous clinical oversight, 24/7 support, and fast delivery, giving patients an accessible path to sustainable weight loss backed by medical expertise.

GLP-1 Medications Driving a New Era in Weight Management

Semaglutide, a GLP-1 receptor agonist, works by reducing appetite, improving satiety, and stabilizing blood sugar levels. Clinical studies show that GLP-1 medications can help patients achieve 15-18% average weight reduction over time when combined with healthy lifestyle changes.

"GLP-1 medications like semaglutide have redefined medical weight loss," said a MedVi Wellness spokesperson. "By offering compounded semaglutide at an affordable price point with physician oversight, we are eliminating the barriers that keep most patients from accessing this transformative therapy."

Key Features of MedVi's GLP-1 Medication Program

*
Compounded Semaglutide Injections - Once-weekly dosing with pre-filled pens

*
Oral Semaglutide Tablets - A non-injectable option for daily use

*
Physician-Supervised Treatment - Personalized dosing plans from board-certified providers

*
Continuous Monitoring and Support - Unlimited check-ins and 24/7 medical access

*
Fast, Nationwide Delivery - Temperature-controlled shipping direct to patients

MedVi's program also includes GLP-1 medication for blood sugar control, benefiting patients managing type 2 diabetes while addressing weight and metabolic health together.

Addressing Drug Shortages and Rising Demand

Due to ongoing shortages of brand-name GLP-1 drugs like Wegovy Registered and Ozempic Registered , compounded semaglutide has become a vital alternative. MedVi sources exclusively from FDA-regulated, PCAB-accredited compounding pharmacies, ensuring pharmaceutical-grade standards and verified potency.

"By combining GLP-1 medication expertise with streamlined telehealth delivery, MedVi is meeting demand where traditional healthcare has fallen short," the spokesperson added. "Patients no longer need to wait months or pay thousands for care."

Why MedVi?

*
GLP-1 medications starting at $179/month

*
FDA-regulated compounding facilities and U.S.-licensed physicians

*
Transparent, no-membership pricing

*
Money-back guarantee with ongoing medical guidance

*
Service availability in all 50 U.S. states

How It Works

*
Online Medical Evaluation: Complete a secure health assessment at medvi.io [https://medvi.org/intakeform.php?uid=1&oid=5&affid=8&afid=seo&pub=5000].

*
Physician Review: A board-certified provider approves treatment if medically appropriate.

*
Medication Delivery: GLP-1 medication ships directly to the patient's home, with instructions included.

*
Ongoing Support: MedVi provides unlimited consultations, dose adjustments, and 24/7 access to licensed clinicians.

About MedVi Wellness

MedVi Wellness is a U.S.-based telehealth platform dedicated to weight loss and metabolic care through GLP-1 medications. By pairing clinical expertise with convenience and affordability, MedVi empowers patients to achieve lasting health results with doctor-led guidance and transparent pricing.

Media Contact
Company Name: MedVi Wellness
Contact Person: Media Relations
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=medvi-expands-access-to-glp1-medication-compounded-semaglutide-for-healthy-living]
Phone: (323) 690-1564
Address:131 Continental Dr. Ste 305
City: Newark
State: DE 19713
Country: United States
Website: http://medvi.io

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.